Literature DB >> 7515909

Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells.

P T Daniel1, P H Krammer.   

Abstract

We have previously described the APO-1 (CD95) cell surface molecule, a novel member of the nerve growth factor/TNF receptor superfamily, identical with the Fas Ag. Triggering of APO-1-induced apoptosis in APO-1+, apoptosis sensitive cells. The data in this study demonstrate that human peripheral blood B cells acquire sensitivity to APO-1-mediated apoptosis on PWM activation. To also study APO-1-mediated apoptosis in an Ag-specific human B cell response, we reconstituted severe combined immunodeficient (SCID) mice i.p. with human PBMC (SCID-hu mice). SCID-hu mice were then injected i.p. with soluble, adjuvant-free tetanus toxoid or diphtheria toxoid, respectively, directly after transfer of the PBMC (day 1) and received an Ag-booster injection on day 14. Two weeks after PBMC transfer human Abs were detected and shown to be Ag specific. SCID-hu mice co-injected with monoclonal anti-APO-1 Ab (IgG3,k) showed significantly suppressed anti-tetanus toxoid or anti-diphtheria toxoid titers, respectively. Sensitivity to anti-APO-1-mediated suppression was only observed in Ag-activated cells from day 0 to day 6 after Ag immunization. Suppression of Ab titers correlated with a decrease of Ag-specific Ig-secreting cells. Re-injection of syngeneic T cells and Ag did not reverse anti-APO-1-induced suppression. These data show a direct suppressive effect of anti-APO-1 on Ag-activated, "specific" B cells. Thus, APO-1-mediated apoptosis in Ag-activated B cells may contribute to the regulation of the humoral immune response.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7515909

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

Review 1.  Molecular mechanisms of irradiation-induced apoptosis.

Authors:  Lei Zhou; Rong Yuan; Lanata Serggio
Journal:  Front Biosci       Date:  2003-01-01

2.  Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.

Authors:  M W Bennett; J O'connell; G C O'sullivan; D Roche; C Brady; J Kelly; J K Collins; F Shanahan
Journal:  Gut       Date:  1999-02       Impact factor: 23.059

Review 3.  The Fas counterattack: a molecular mechanism of tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J K Collins; F Shanahan
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  A distinct plasmablast and naïve B-cell phenotype in primary immune thrombocytopenia.

Authors:  Shaun M Flint; Adele Gibson; Geoff Lucas; Raghava Nandigam; Louise Taylor; Drew Provan; Adrian C Newland; Caroline O Savage; Robert B Henderson
Journal:  Haematologica       Date:  2016-03-11       Impact factor: 9.941

Review 5.  Fas expression and apoptosis in human B cells.

Authors:  E Schattner; S M Friedman
Journal:  Immunol Res       Date:  1996       Impact factor: 2.829

6.  Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilege.

Authors:  J O'Connell; M W Bennett; G C O'Sullivan; J O'Callaghan; J K Collins; F Shanahan
Journal:  Clin Diagn Lab Immunol       Date:  1999-07

Review 7.  Differentiation and apoptosis of human germinal center B-lymphocytes.

Authors:  Y S Choi
Journal:  Immunol Res       Date:  1997       Impact factor: 2.829

Review 8.  Regulation of autoreactive anti-IgG (rheumatoid factor) B cells in normal and autoimmune mice.

Authors:  H Wang; M J Schlomchik
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

9.  Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5).

Authors:  Andres Forero-Torres; Jatin Shah; Tina Wood; James Posey; Ronda Carlisle; Catherine Copigneaux; Feng Roger Luo; Slawomir Wojtowicz-Praga; Ivor Percent; Mansoor Saleh
Journal:  Cancer Biother Radiopharm       Date:  2010-02       Impact factor: 3.099

10.  IL-7 sensitizes human pre-B cells but not pro-B cells to Fas/APO-1 (CD95)-mediated apoptosis.

Authors:  Y Levy; K Benlagha; A Buzyn; M Colombel; J C Brouet; K Lassoued
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.